Document Detail


Transdermal testosterone may improve ovarian response to gonadotrophins in low-responder IVF patients: a randomized, clinical trial.
MedLine Citation:
PMID:  19054777     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Studies in macaques have indicated that androgens have some synergistic effects with FSH on folliculogenesis. This study investigated the usefulness of pretreatment with transdermal testosterone in low-responder IVF patients. METHODS: Randomized clinical trial including 62 infertile women who had a background of the first IVF treatment cycle cancelled because of poor follicular response. Patients were randomized in two treatment groups in their second IVF attempt. In patients in Group 1 (n = 31), transdermal application of testosterone preceding standard gonadotrophin ovarian stimulation under pituitary suppression was used. In Group 2 (n = 31 patients), ovarian stimulation was carried out with high-dose gonadotrophin in association with a minidose GnRH agonist protocol. The primary end-point was the incidence of low-responder patients. The main secondary outcome was the incidence of patients reaching ovum retrieval. RESULTS: The percentage of cycles with low response was significantly lower in Group 1 than in Group 2 (32.2 versus 71% 95% confidence interval for the difference, 15.7-61.6; P < 0.05). The number of patients with ovum retrieval tended to be higher in Group 1 than in Group 2 (80.6 versus 58.1% P = 0.09), the difference reaching statistical significance (81.2 versus 41.1%; P < 0.05) when only patients having normal basal FSH levels (16 and 17 patients in Groups 1 and 2, respectively) were considered. CONCLUSIONS: Pretreatment with transdermal testosterone may improve the ovarian sensitivity to FSH and follicular response to gonadotrophin treatment in previous low-responder IVF patients. This approach leads to an increased follicular response compared with a high-dose gonadotrophin and minidose GnRH agonist protocol.
Authors:
Francisco Fábregues; Joana Peñarrubia; Montserrat Creus; Dolors Manau; Gemma Casals; Francisco Carmona; Juan Balasch
Related Documents :
8485607 - Comparative efficacy of gestrinone and danazol in infertile women with endometriosis.
22632497 - Prospective clinical study of a novel left atrial appendage occlusion device.
22808827 - Strength comparison of mitral annuloplasty ring and suturing combinations: an in-vitro ...
2569267 - Hormonal therapy for cryptorchidism with a combination of human chorionic gonadotropin ...
23329227 - The association between early atrial arrhythmia and long-term return to sinus rhythm fo...
9041287 - Megestrol acetate treatment of growth failure in children infected with human immunodef...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-12-03
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  24     ISSN:  1460-2350     ISO Abbreviation:  Hum. Reprod.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-16     Completed Date:  2009-04-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  England    
Other Details:
Languages:  eng     Pagination:  349-59     Citation Subset:  IM    
Affiliation:
Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine-University of Barcelona, C/Casanova 143, 08036- Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adult
Androgens / administration & dosage,  adverse effects,  therapeutic use*
Chorionic Gonadotropin / blood
Estradiol / blood
Female
Fertilization in Vitro*
Follicle Stimulating Hormone / blood
Gonadotropins / therapeutic use*
Humans
Infertility, Female / drug therapy,  ultrasonography
Luteinizing Hormone / blood
Oocyte Retrieval
Ovary / drug effects
Testosterone / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Androgens; 0/Chorionic Gonadotropin; 0/Gonadotropins; 50-28-2/Estradiol; 58-22-0/Testosterone; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Viability of bovine embryos following exposure to the green filtered or wider bandwidth light during...
Next Document:  Rates of preterm birth following antenatal maternal exposure to severe life events: a population-bas...